my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
17-04-2009: Sanofi-aventis announced that it has signed a binding agreement for the acquisition of BiPar Sciences, Inc., a privately held US biopharmaceutical company, developing novel tumorselective approaches for the treatment of different types of cancers.
BiPar is a company in the emerging field of DNA (DeoxyriboNucleic Acid) repair using PARP (Poly ADP-Ribose Polymerase) inhibitors. PARP inhibitors represent a new, targeted approach to treating many types of cancers. By preventing cancer cells from repairing their own DNA, PARP inhibitors ultimately cause cancer cell death.
BiPar’s lead product candidate is BSI-201, a potential first-in-class PARP inhibitor currently being studied in Phase 2 clinical trials in metastatic triple negative breast cancer (TNBC), ovarian cancer and other malignancies.
Under the agreement, the purchase price will depend on the achievement of milestone payments related to the development of BSI-201 which could achieve a maximum of $ 500 M. The closing of the transaction is expected to occur in the 2nd quarter of 2009, subject to the receipt of the FTC clearance.
Contact / Request information
Request further information free of charge:
Watchlist
This is where you can add this news to your personal favourites
Oncodesign announced that the company has entered into a strategic research collaboration with Sanofi to apply exclusively Oncodesign’s Nanocyclix(R) technology to several Sanofi kinase target programs. Nanocyclix(R) is a proprietary medicinal chemistry technology and research platform bas ... more
Algeta ASA announced that its research collaboration with Sanofi (previously Genzyme) has been extended. This collaboration, which was announced in April 2011, is focused on evaluating the potential of linking the alpha-emitter thorium-227 to a proprietary antibody from Genzyme to create a ... more
Sanofi Canada invests in prostate cancer research
Sanofi Canada is supporting a five-year study on radiation therapy and prostate cancer. Dr. Tamim Niazi of the Quebec Radiation Oncology GU Group and the JGH is the lead researcher. Sanofi Canada President and CEO, Hugh O'Neill and members of Sanofi's Oncology Team celebrate the collaboration. more
Sanofi-Aventis Deutschland GmbH
Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris and in New York. Sanofi Pasteur, the vaccines division of sanofi-aventis Group, provided more than a billi ... more
Sanofi-Aventis Deutschland GmbH
Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris and in New York. Sanofi Pasteur, the vaccines division of sanofi-aventis Group, provided more than a billi ... more
Sanofi-Aventis Deutschland GmbH
Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris and in New York. Sanofi Pasteur, the vaccines division of sanofi-aventis Group, provided more than a billi ... more
Sanofi-aventis: BSI-201 enters phase III in metastatic triple negative breast cancer
Sanofi-aventis and its wholly owned subsidiary, BiPar Sciences, announced the initiation of the pivotal Phase III trial for BSI-201 in combination with chemotherapy in patients with metastatic triple-negative breast cancer (mTNBC), defined by tumors lacking expression of estrogen, progester ... more
Sanofi-aventis to acquire BiPar Sciences, a US biopharmaceutical company
Sanofi-aventis announced that it has signed a binding agreement for the acquisition of BiPar Sciences, Inc., a privately held US biopharmaceutical company, developing novel tumorselective approaches for the treatment of different types of cancers. BiPar is a company in the emerging field o ... more
BiPar Sciences is a privately held biopharmaceutical company pioneering novel tumor-selective therapies designed to address urgent unmet needs of cancer patients, with headquarters in Brisbane, California. In addition to BSI-201, the company also has two additional compounds in pre-clinical ... more
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
